Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance — Stella
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(6 sites)
France
Gustave Roussy, Villejuif, France
Institut Bergonié, Bordeaux
Centre Georges François Leclerc, Dijon
Institut Paoli Calmettes, Marseille
Institut de Cancérologie de l'Ouest, Saint-Herblain
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy